Literature DB >> 29134440

Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.

Günter Klöppel1, Stefano La Rosa2.   

Abstract

In 1983, a monoclonal antibody, Ki67, was generated, that labeled the nuclei of proliferating non-neoplastic and neoplastic cells. The name Ki67 derived from the city of Kiel (Ki) where the antibody was produced in the university department of pathology and refers to the number of the original clone (67). Systematic assessment of the proliferative activity of tumors using Ki67 started in the 1990s, when Ki67, which only worked on frozen tissue, was complemented by the antibody MIB-1 that also worked in formalin-fixed tissues. Pancreatic neuroendocrine neoplasms (PanNENs) were the first endocrine tumors whose proliferative activity was assessed with Ki67. This approach was so successful that Ki67 was included as prognostic marker in the 2000 and 2004 WHO classifications of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). In 2010, the WHO classification of GEP-NENs introduced a three-tiered grading, originally proposed by ENETS in 2006 that was mainly based on the Ki67 index. As it has subsequently been shown that the Ki67 index is the most reliable factor in the prognostic evaluation of GEP-NENs, especially of PanNENs, the 2017 WHO classification of PanNENs requires its use and strongly recommends exact assessment of the proportion Ki67-labeled cells as basis for the calculation of the Ki67 index. Problems in assessing the Ki67 index include intertumoral and intratumoral staining heterogeneity and counting methods. Despite such problems, the Ki67 index has emerged as indispensable for the prognostic and therapeutic stratification of the majority of GEP-NENs and can barely be replaced by counting mitoses. In future, however, it can be anticipated that the Ki67 cut-offs experience refinement in relation to the type of tumor, its location, and its response to therapy. It is also possible that the prognostic risk of an individual tumor is calculated for each Ki67 unit and not for an "a priori" fixed Ki67 class.

Entities:  

Keywords:  Assessment; History; Intestine; Ki67; Neuroendocrine neoplasms; Pancreas; Prognostic marker; Stomach

Mesh:

Substances:

Year:  2017        PMID: 29134440     DOI: 10.1007/s00428-017-2258-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  62 in total

1.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

2.  The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.

Authors:  Olca Basturk; Zhaohai Yang; Laura H Tang; Ralph H Hruban; Volkan Adsay; Chad M McCall; Alyssa M Krasinskas; Kee-Taek Jang; Wendy L Frankel; Serdar Balci; Carlie Sigel; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2015-05       Impact factor: 6.394

Review 3.  Revised classification of neuroendocrine tumours of the lung, pancreas and gut.

Authors:  C Capella; P U Heitz; H Höfler; E Solcia; G Klöppel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

4.  Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count.

Authors:  Volkan Adsay
Journal:  Am J Surg Pathol       Date:  2012-12       Impact factor: 6.394

5.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

6.  Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.

Authors:  Francesco Panzuto; Letizia Boninsegna; Nicola Fazio; Davide Campana; Maria Pia Brizzi; Gabriele Capurso; Aldo Scarpa; Filippo De Braud; Luigi Dogliotti; Paola Tomassetti; Gianfranco Delle Fave; Massimo Falconi
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

7.  Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.

Authors:  Björn Konukiewitz; Anna Melissa Schlitter; Moritz Jesinghaus; Dominik Pfister; Katja Steiger; Angela Segler; Abbas Agaimy; Bence Sipos; Giuseppe Zamboni; Wilko Weichert; Irene Esposito; Nicole Pfarr; Günter Klöppel
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

8.  Clinical outcomes of rectal neuroendocrine tumors ≤ 10 mm following endoscopic resection.

Authors:  Gwang-Un Kim; Kyung-Jo Kim; Seung-Mo Hong; Eun-Sil Yu; Dong-Hoon Yang; Kee Wook Jung; Byong Duk Ye; Jeong-Sik Byeon; Seung-Jae Myung; Suk-Kyun Yang; Jin-Ho Kim
Journal:  Endoscopy       Date:  2013-11-28       Impact factor: 10.093

Review 9.  Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice.

Authors:  Giuseppe Pelosi; Guido Rindi; William D Travis; Mauro Papotti
Journal:  J Thorac Oncol       Date:  2014-03       Impact factor: 15.609

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  36 in total

1.  DWI and IVIM are predictors of Ki67 proliferation index: direct comparison of MRI images and pathological slices in a murine model of rhabdomyosarcoma.

Authors:  Yuan Yuan; Dewei Zeng; Yajie Liu; Juan Tao; Yu Zhang; Jie Yang; Tsendjav Lkhagvadorj; Zhenzhen Yin; Shaowu Wang
Journal:  Eur Radiol       Date:  2019-11-08       Impact factor: 5.315

Review 2.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

Review 3.  Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms.

Authors:  Georgios Kyriakopoulos; Vasiliki Mavroeidi; Eleftherios Chatzellis; Gregory A Kaltsas; Krystallenia I Alexandraki
Journal:  Ann Transl Med       Date:  2018-06

Review 4.  A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal.

Authors:  C Villa; A Vasiljevic; M L Jaffrain-Rea; O Ansorge; S Asioli; V Barresi; L Chinezu; M P Gardiman; A Lania; A M Lapshina; L Poliani; L Reiniger; A Righi; W Saeger; J Soukup; M Theodoropoulou; S Uccella; J Trouillas; F Roncaroli
Journal:  Virchows Arch       Date:  2019-10-02       Impact factor: 4.064

Review 5.  Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.

Authors:  Silvia Uccella; Stefano La Rosa; Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

6.  Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11.

Authors:  Giorgio A Croci; Eva Hoster; Sílvia Beà; Guillem Clot; Anna Enjuanes; David W Scott; José Cabeçadas; Luis Veloza; Elias Campo; Erik Clasen-Linde; Rashmi S Goswami; Lars Helgeland; Stefano Pileri; Grzegorz Rymkiewicz; Sarah Reinke; Martin Dreyling; Wolfram Klapper
Journal:  Virchows Arch       Date:  2020-01-23       Impact factor: 4.064

7.  Diagnosis and prognostic significance of extramural venous invasion in neuroendocrine tumors of the small intestine.

Authors:  Qingqing Liu; Alexandros D Polydorides
Journal:  Mod Pathol       Date:  2020-06-08       Impact factor: 7.842

Review 8.  Neuroendocrine neoplasms of the esophagus and stomach.

Authors:  Luca Mastracci; Guido Rindi; Federica Grillo; Enrico Solcia; Michela Campora; Matteo Fassan; Paola Parente; Alessandro Vanoli; Stefano La Rosa
Journal:  Pathologica       Date:  2021-02

Review 9.  Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms.

Authors:  Stefano La Rosa
Journal:  Endocr Pathol       Date:  2021-03-31       Impact factor: 3.943

10.  The role of mineralocorticoids and glucocorticoids under the impact of 11β-hydroxysteroid dehydrogenase in human breast lesions.

Authors:  Mingzhen Cai; Keely McNamara; Yuto Yamazaki; Narumi Harada; Minoru Miyashita; Hiroshi Tada; Takanori Ishida; Hironobu Sasano
Journal:  Med Mol Morphol       Date:  2022-02-01       Impact factor: 2.309

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.